Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day…
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day…
HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) — Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”),…
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the…
SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (CARGO), a biotechnology…
SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (CARGO), a biotechnology…
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with…
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with…
Company receives highest average rating across all 26 performance attributes out of 34 CROs included…
Company receives highest average rating across all 26 performance attributes out of 34 CROs included…
Once granted, this patent will provide intellectual property protection until December 2040, and may qualify…
Once granted, this patent will provide intellectual property protection until December 2040, and may qualify…
BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical…
BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical…
REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company…
REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company…
She will remain a member of the COMPASS Pathways Board of Directors LONDON, May 31,…
She will remain a member of the COMPASS Pathways Board of Directors LONDON, May 31,…
Full read-out of the Phase 1/2a trial of EVX-02 in 10 patients with completely resected…
Full read-out of the Phase 1/2a trial of EVX-02 in 10 patients with completely resected…
– TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily…